Quarterly Result30 Jan 2026, 08:52 pm
Astec Lifesciences Reports Q3FY26 Financial Results: Revenue Growth, Improved Margins, and Positive EBITDA
AI Summary
Astec Lifesciences Limited has announced its financial results for the third quarter and nine months ended December 31, 2025. The company reported consolidated total income of Rs. 125.5 crore in Q3FY26, representing a 31% increase from Q3FY25. The company's EBITDA stood at Rs. 4.8 crore in Q3FY26, compared to an EBITDA loss of Rs. 3.8 crore in Q3 FY25. The company reported a loss of Rs. 15.7 crore in Q3FY26, an improvement from the loss of Rs. 40.4 crore in Q3FY25. For the nine-month period ended December 31, 2025, the company reported a loss of Rs. 73.1 crore, compared to a loss of Rs. 118.6 crore in the same period last year.
Key Highlights
- 1.3x growth in revenue over Q3 FY25, driven by higher Enterprise volumes and improved Contract Manufacturing segment off-take.
- Sequential revenue increase of 1.7x over Q2 FY26, primarily due to CDOMO off-take.
- Improvement in Enterprise margins and higher COMO volume off-take contributing to overall margin improvement.
- Positive EBITDA of Rs. 4.8 crore in Q3 FY26.
- Loss reduction in Q3FY26 to Rs. 15.7 crore from Rs. 40.4 crore in Q3FY25.